Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Thrombocytosis 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hypereosinophilic Syndrome 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Rituximab 44Cyclophosphamide 38Prednisone 26Doxorubicin 25Vincristine 20Magnetic Resonance Spectroscopy 20Lenalidomide 19Specimen Handling 18Gemcitabine 18Biopsy 15polatuzumab vedotin 14Oxaliplatin 14glofitamab 12obinutuzumab 11ibrutinib 10Etoposide 10CT-P10 9fludarabine 8Dexamethasone 8prednylidene 7pembrolizumab 7deltacortene 7Prednisolone 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7venetoclax 6tafasitamab 6acalabrutinib 6fludarabine phosphate 5R-CHOP protocol 5Immunotherapy, Adoptive 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × pevonedistat × 90 days × Clear all
NCT03479268 2026-04-27

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

City of Hope Medical Center

Phase 1 Active not recruiting
18 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡